ArticleAdvanced healthcare materials2015
Spatially organized differentiation of mesenchymal stem cells within biphasic microparticle-incorporated high cell density osteochondral tissues.
Article in Advanced healthcare materials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Cell Contractile Force-Mediated Morphogenetic Tissue Engineering via 4D Printed Degradable Hydrogel Scaffolds.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cell Contractile Forces Drive Spatiotemporal Morphogenesis in 4D Bioprinted Living Constructs.Matter · 2025Article
- Osteochondral organoids: current advances, applications, and upcoming challenges.Stem cell research & therapy · 2024Review
- Article
- The Role of Microsphere Structures in Bottom-Up Bone Tissue Engineering.Pharmaceutics · 2023Review
- Decellularized Human Umbilical Tissue-Derived Hydrogels Promote Proliferation and Chondrogenic Differentiation of Mesenchymal Stem Cells.Bioengineering (Basel, Switzerland) · 2022Article
- Article
- Formation of Osteochondral Organoids from Murine Induced Pluripotent Stem Cells.Tissue engineering. Part A · 2021Article
- Hydrogel microspheres for spatiotemporally controlled delivery of RNA and silencing gene expression within scaffold-free tissue engineered constructs.Acta biomaterialia · 2021Article
- Utility of Air Bladder-Derived Nanostructured ECM for Tissue Regeneration.Frontiers in bioengineering and biotechnology · 2020Article
- Assembly of Tissue-Engineered Blood Vessels with Spatially Controlled Heterogeneities.Tissue engineering. Part A · 2018Article
- Glycosylated superparamagnetic nanoparticle gradients for osteochondral tissue engineering.Biomaterials · 2018Article
- Dual non-viral gene delivery from microparticles within 3D high-density stem cell constructs for enhanced bone tissue engineering.Biomaterials · 2018Article
- Engineering the Surface of Therapeutic "Living" Cells.Chemical reviews · 2018Review
- High-density human mesenchymal stem cell rings with spatiotemporally-controlled morphogen presentation as building blocks for engineering bone diaphyseal tissue.Nanotheranostics · 2018Article
- Pathogenic roles of microvesicles in diabetic retinopathy.Acta pharmacologica Sinica · 2018Review
- Cell and Biologic-Based Treatment of Flexor Tendon Injuries.Operative techniques in orthopaedics · 2016Article
- Spatial regulation of controlled bioactive factor delivery for bone tissue engineering.Advanced drug delivery reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Giving rise to both bone and cartilage during development, bone marrow-derived mesenchymal stem cells (hMSC) have the unique capacity to generate the complex tissues of the osteochondral interface. Utilizing a scaffold-free hMSC system, biphasic osteochondral constructs are incorporated with two types of growth factor-releasing microparticles to enable spatially organized differentiation. Gelatin microspheres (GM) releasing transforming growth factor-β1 (TGF-β1) combined with hMSC form the chondrogenic phase. The osteogenic phase contains hMSC only, mineral-coated hydroxyapatite microparticles (MCM), or MCM loaded with bone morphogenetic protein-2 (BMP-2), cultured in medium with or without BMP-2. After 4 weeks, TGF-β1 release from GM within the cartilage phase promotes formation of a glycosaminoglycan- and type II collagen-rich matrix, and has a local inhibitory effect on osteogenesis. In the osteogenic phase, type X collagen and osteopontin are produced in all conditions. However, calcification occurs on the outer edges of the chondrogenic phase in some constructs cultured in media containing BMP-2, and alkaline phosphatase levels are elevated, indicating that BMP-2 releasing MCM provides better control over region-specific differentiation. The production of complex, stem cell-derived osteochondral tissues via incorporated microparticles could enable earlier implantation, potentially improving outcomes in the treatment of osteochondral defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.